Co-incidence of Biomarker Aberrations in the presence or absence of PIK3CA or PTEN Mutations

Table 1. Aggregate differences in gene mutation rates, protein expression rates, and copy number were measured and shown between PIK3CA WT and PIK3CA MT patients and between PTEN WT and PTEN MT cases.

B. Total mutations identified out of total cases tested, each, for PIK3CA or PTEN.

PTEN mutations and mutation or loss of PTEN. These alterations may contribute to PIK3CA WT patients and co-incident with hormone receptors or HER2. Multiple aberrations, including but not limited to mutations in KRAS, BRAF, TP53, and PTEN alterations, may co-exist with PIK3CA or PTEN anomalies. PIK3CA mutation, PTEN mutation and PTEN loss are found in an important subset of multiple tumor types and may be targeted by inhibitors. Optimization of the drug used may require determining the specific types of aberration seen, e.g., HELC+ vs. HELC- (PIK3CA).